{
  "abstract": "The US Food and Drug Administration (FDA) has written to the maker of the glucagon-like peptide-1 (GLP-1) receptor agonist weight loss drug Wegovy (semaglutide), saying that its first direct to consumer TV advertisement for a new pill form is misleading and overstates the drug’s benefits.1",
  "authors": [
    {
      "affiliations": [
        "Montreal"
      ],
      "name": "Owen Dyer"
    }
  ],
  "title": "Wegovy: FDA accuses Novo Nordisk of “false or misleading” ad for weight loss pill",
  "uid": "53638ba1-6175-5b74-98aa-50b5768d5f48"
}